Patients with SLE on different treatments at participating sites, sorted by country
| Country | Patients with SLE | Patients with SLE on RTX (%) | Patients with SLE on conventional immunosuppressive therapy (%) |
|---|---|---|---|
| Belgium* | 5000 | 1 | 30 |
| Denmark | 250 | 2 | 50 |
| France* | 22 500 | 1.6† | – |
| Germany | 325 | 4 | 92 |
| Greece | 500 | 3 | – |
| Hungary | 250 | 1 | 40 |
| Italy | 200–400 | 3–4 | 20–62 |
| Spain | 5–900 | 0–11 | 19–70 |
| Sweden | 250–350 | 4–20 | 40–65 |
| The Netherlands | 200–275 | 1–4 | 20–25 |
| Turkey | 600 | 4 | 42 |
| UK | 450 | 7 | 85 |
*Figures are representative for the whole country.
†Derived from the number of patients (160) in the nationwide Autoimmunity and Rituximab (AIR) registry, which represents about 50% of patients with SLE on RTX.
RTX, rituximab; SLE, systemic lupus erythematosus.